The Life Sciences team advised Intellia Therapeutics, Inc. (Nasdaq: NTLA) on its $690 million underwritten public offering on the heels of releasing the first-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans.
Intellia is a leading clinical-stage genome editing company focused on developing novel, potentially curative therapeutics using CRISPR/Cas9 technology. To fully realize the transformative potential of CRISPR/Cas9, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by removing, re-engineering and re-infusing the patient’s own cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of CRISPR/Cas9 to create new classes of genetic medicine.
The NTLA-2001 global clinical program is an open-label, multi-center, two-part Phase 1 study in adults with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). NTLA-2001 is designed to inactivate the TTR gene in liver cells to prevent the production of misfolded transthyretin (TTR) protein, which accumulates in tissues throughout the body and causes the debilitating and often fatal complications of ATTR amyloidosis. The trial’s primary objectives are to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of NTLA-2001. On June 26, 2021, Intellia and Regeneron Pharmaceuticals, Inc. announced landmark clinical data showing a deep reduction in disease-causing protein after a single infusion. NTLA-2001 is the first CRISPR/Cas9-based therapy candidate to be administered systemically, via intravenous infusion, for precision editing of a gene in a target tissue in humans.
In its public offering, Intellia sold 4,758,620 shares of its common stock at a public offering price of $145.00 per share, including the exercise in full by the underwriters of their option to purchase up to an additional 620,689 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $690 million.
Goodwin has advised Intellia since the company’s inception and Series A financing in 2015, through several rounds of private financing, its public market debut, and beyond.
The Goodwin team providing ongoing advisory to Intellia is led by Arthur McGivern. The team counseling the company on the latest offering included Gaby Morales-Rivera, Daniel Hughes, Pablo Hernandez-Romero, Evan DeYcaza, Janet Andolina, Alex Varond, Nikhil Sethi, Sarah Wicks, Maggie Wong, and Pamela Finan.